

Organized by



Supported by



# 7<sup>th</sup> Annual International Review in Head & Neck Cancers

28<sup>th</sup> - 29<sup>th</sup> September, 2024

Venue: Royal Palace, NSCI, Worli, Mumbai

2023

2024

## Organizing Chairperson

Dr. B. K. Smruti  
Dr. Mehul Bhansali  
Dr. Kumar Prabhash

## Organizing Secretaries

Dr. Vijay Patil  
Dr. Rakesh Katna  
Dr. Sarbani Laskar

## Jt. Organizing Secretaries

Dr. Shivkumar Thiagarajan  
Dr. Ashay Karpe  
Dr. Trinanjan Basu

## Scientific Committee Chair

Dr. Vanita Noronha

Click on the link below for registration  
<https://riverroute.in/arhnc2024>

Managed by  
**riverroute**<sup>®</sup>

Organized by



Supported by



# 7<sup>th</sup> Annual International Review in Head & Neck Cancers

28<sup>th</sup> - 29<sup>th</sup> September, 2024

Venue: Royal Palace, NSCI, Worli, Mumbai

2023

2024

Dear Colleagues,

We are honored to extend a warm invitation to you for the **"7<sup>th</sup> Annual International Conference in Head and Neck Cancer"**, scheduled to take place on the **28<sup>th</sup> and 29<sup>th</sup> of September, 2024**, at the **Royal Palace, NSCI, Worli, Mumbai**. This meeting is hosted by Mumbai Oncology Association and supported by Indian Society of Paediatric and Medical Oncology and Cancer Research and Statistic Trust.

This conference promises to be a remarkable event, bringing together leading experts, researchers, and clinicians in the field of head and neck cancer. Over the course of two days, we will delve into **the most significant and cutting-edge publications and abstracts, carefully selected from national and international journals and conferences**.

The top 80 publications, chosen for their innovative contributions and clinical relevance, will be presented in a structured and detailed manner, categorized by site-specific and treatment-specific themes. **Each oral presentation will be followed by an engaging panel discussion, allowing for an in-depth exploration of the applicability of these findings in clinical practice**.

Your presence and participation would be invaluable to the success of this event. We are confident that your insights and expertise will greatly enrich the discussions and contribute to the advancement of our collective knowledge and practice in this crucial field.

We look forward to welcoming you to Mumbai and to what promises to be an inspiring and intellectually stimulating conference.

Warm regards,

Dr. B. K. Smruti  
Dr. Mehul Bhansali  
Dr. Kumar Prabhash

Click on the link below for registration  
<https://riverroute.in/arhnc2024>

Managed by

riverroute®

Organized by



Supported by

**CRST**  
Cancer Research, Statistics and Treatment



# 7<sup>th</sup> Annual International Review in Head & Neck Cancers

**28<sup>th</sup> - 29<sup>th</sup> September, 2024**

**Venue: Royal Palace, NSCI, Worli, Mumbai**

**2023**

**2024**

## Scientific Committee

Dr. Sewanti Limaye	Dr. Rohit Pai
Dr. Nandini Menon	Dr. Mansi Khanderia
Dr. Minit Shah	Dr. Sunil Chopade
Dr. Manjusha Vagal	Dr. Anuj Kumar
Dr. Poonam Joshi	Dr. Rakesh Katna
Dr. Arjun Singh	Dr. Abhishek Mahajan
Dr. Shivshankar Timmanpyati	Dr. Mandar Deshpande
Dr. Karan Gupta	Dr. Arun Balaji
Dr. Rushabh Kothari	Dr. Akhil Kapoor
Dr. Prahalad Yathiraj	Dr. Kaustav Talapatra
Dr. Shwetabh Sinha	Dr. Nikhil Kalyani
Dr. Deepak Balasubramaniam	Dr. Nikhilesh Borkar
Dr. Monali Swain	Dr. Shilpi Sharma
Dr. Goutam Panda	Dr. Suyash Kulkarni
Dr. Rakesh Pinniti	Dr. Mukul Roy
Dr. Bhuvan Chugh	Dr. Vaibhav Chaudhary
Dr. Dushyant Mandlik	Dr. Kunal Jobunputra
Dr. Neha Mittal	Dr. Anabarsan Sekar
Dr. Krishnakumar Thankappan	Dr. Deep Vora
Dr. Anuradha Daptardar	Dr. Aman Sharma
Dr. Anshul Singla	Dr. Srinivas Kulkarni
Dr. Deepanjali Andulkar	Dr. Kshitij Domadia
Dr. Kinjal Jani	Dr. Gaurav Prakash

Click on the link below for registration  
<https://riverroute.in/arhnc2024>

Managed by

**riverroute**<sup>®</sup>

Organized by



Supported by



# 7<sup>th</sup> Annual International Review in Head & Neck Cancers

28<sup>th</sup> - 29<sup>th</sup> September, 2024

Venue: Royal Palace, NSCI, Worli, Mumbai

2023

2024

## Scientific Program

28<sup>th</sup> September, 2024 — Day 1

09:00am - 01:00pm

**Session Coordinators: Dr. Laboni Sarkar, Dr. Devanshee Shah**

**SESSION 1: Key abstracts to be presented on cancers of oral cavity**

09:00am - 09:10am

**CHAIRPERSONS: Dr. Vivek Anand, Dr. Mehul Bhansali**

**Reviewer: Dr. Shivakumar Thiagarajan**

Transoral robotic surgery without adjuvant therapy: A systematic review and meta-analysis of the association between surgical margins and local recurrence.

**Author:** Andrew Williamson

**Citation:** Oral Oncol. 2023 Dec:147:106610

Long-term outcomes of neo-adjuvant chemotherapy on borderline resectable oral cavity cancers: Real-world data of 3266 patients and implications for clinical practice.

**Author:** Vanita Noronha

**Citation:** 2024 Jan:148:106633

09:10am - 09:20am

**Reviewer: Dr. Prahalad Yathiraj**

Adjuvant radiotherapy mitigates impact of perineural invasion on oncologic outcomes in early-stage oral cavity squamous cell carcinoma. A multi-institutional analysis of 557 patients

**Author:** Andrew J Holcomb

**Citation:** Oral Oncol. 2023 Jul:142:106420

The impact of multifocal perineural invasion in predicting survival in patients with oral squamous cell carcinoma: A multicenter investigation

**Author:** Shaheen Hasmat

**Citation:** Head Neck. 2023 Oct; 45(10):2605-2612  
NOVEMBER 01, 2022

Click on the link below for registration  
<https://riverroute.in/arhnc2024>

Managed by

riverroute®

Organized by



Supported by



# 7<sup>th</sup> Annual International Review in Head & Neck Cancers

28<sup>th</sup> - 29<sup>th</sup> September, 2024

Venue: Royal Palace, NSCI, Worli, Mumbai

2023

2024

## Scientific Program

28<sup>th</sup> September, 2024 — Day 1

09:20am - 09:30am	<p><b>Reviewer: Dr. Anshul Singla</b></p> <p>Health-related quality of life, functional outcomes, and complications after sentinel lymph node biopsy and elective neck dissection in early oral cancer: A systematic review <b>Author:</b> Christopher McDonald MFDS, FRCS <b>Citation:</b> Head Neck. 2023 Nov;45(11):2754-2779</p>
	<p>Oral cavity adjuvant therapy (OCAT) -a phase III, randomized controlled trial of surgery followed by conventional RT (5 fr/wk) versus concurrent CT-RT versus accelerated RT (6fr/wk) in locally advanced, resectable, squamous cell carcinoma of oral cavity. <b>Author:</b> Sarbani G. Laskar <b>Citation:</b> EJC ORIGINAL RESEARCH  VOLUME 181, P179-187, MARCH 2023</p>
	<p><b>CHAIRPERSONS: Dr. Vijay Haribhakti, Dr. Shyam Shrivastava</b></p>
09:30am - 10:00am	<p><b>Panel discussion on presented key abstracts of cancers of oral cavity</b></p> <p><b>MODERATOR: Dr. Vikram Kekatpure</b></p> <p><b>PANELISTS: Dr. Yusuf Mistry, Dr. Nikhilesh Borkar, Dr. Ashwini Budrukkar, Dr. Salil Patkar, Dr. Suparna Rao, Dr. Anuj Kumar PG, Dr. Prahalad Yathiraj</b></p>

Click on the link below for registration  
<https://riverroute.in/arhnc2024>

Managed by

riverroute®

Organized by



Supported by



# 7<sup>th</sup> Annual International Review in Head & Neck Cancers

28<sup>th</sup> - 29<sup>th</sup> September, 2024

Venue: Royal Palace, NSCI, Worli, Mumbai

2023

2024

## Scientific Program

28<sup>th</sup> September, 2024 — Day 1

### SESSION 2: Key abstracts to be presented on Oropharyngeal Cancer

**CHAIRPERSONS: Dr. Sharmila Agarwal, Dr. Girish Phadke**

10:00am - 10:10am

**Reviewer: Dr. Trinanjan Basu**

Phase III randomized trial of intensity-modulated proton therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for the treatment of head and neck oropharyngeal carcinoma (OPC)

**Author:** Steven J. Frank, MD

**Citation:** ASCO Abstract: 6006

Dysphagia-optimised intensity-modulated radiotherapy versus standard intensity-modulated radiotherapy in patients with head and neck cancer (DARS): a phase 3, multicentre, randomised, controlled trial

**Author:** Christopher Nutting

**Citation:** Lancet Oncol., 2023 Aug;24(8):868-880

10:10am - 10:20am

**Reviewer: Dr. Arjun Singh**

Differences in Functional and Survival Outcomes Between Patients Receiving Primary Surgery vs Chemoradiation Therapy for Treatment of T1-T2 Oropharyngeal Squamous Cell Carcinoma

**Author:** Dev R Amin

**Citation:** JAMA Otolaryngol Head Neck Surg., 2023 Nov 1;149(11):980-986

Click on the link below for registration  
<https://riverroute.in/arhnc2024>

Managed by

riverroute®

Organized by



Supported by



# 7<sup>th</sup> Annual International Review in Head & Neck Cancers

28<sup>th</sup> - 29<sup>th</sup> September, 2024

Venue: Royal Palace, NSCI, Worli, Mumbai

2023

2024

## Scientific Program

28<sup>th</sup> September, 2024 — Day 1

	<p>Risk of recurrence after neoadjuvant chemotherapy and transoral robotic surgery in patients with oropharynx cancer that avoid adjuvant radiation  <b>Author:</b> Alisha R. Pershad  <b>Citation:</b> Cancer Med. 2024 Apr; 13(7): e7146</p>
10:20am - 10:30am	<p><b>Reviewer:</b> Dr. Arnav Tongaonkar</p> <p>Neoadjuvant Nivolumab Plus Chemotherapy Followed By Response-Adaptive Therapy for HPV+ Oropharyngeal Cancer: OPTIMA II Phase 2 Open-Label Nonrandomized Controlled Trial  <b>Author:</b> Ari J Rosenberg  <b>Citation:</b> JAMA Oncol. 2024 Jul 1;10(7):923-931</p> <p>Neoadjuvant HPV16-specific arenavirus-based immunotherapy HB-200 plus chemotherapy followed by response-stratified de-intensification in HPV16+ oropharyngeal cancer: TARGET-HPV  <b>Author:</b> Ari Joseph Rosenberg, MD  <b>Citation:</b> ASCO Abstract: 6017</p>
10:30am - 10:40am	<p><b>Reviewer:</b> Dr. Ashwini Budrukkar</p> <p>Intensity-Modulated Radiation Therapy Alone Versus Intensity-Modulated Radiation Therapy and Brachytherapy for Early-Stage Oropharyngeal Cancers: Results From a Randomized Controlled Trial  <b>Author:</b> Ashwini Budrukkar  <b>Citation:</b> Int J Radiat Oncol Biol Phys. 2024; 118:5: 1541-1551</p>

Click on the link below for registration  
<https://riverroute.in/arhnc2024>

Managed by



Organized by



Supported by



# 7<sup>th</sup> Annual International Review in Head & Neck Cancers

28<sup>th</sup> - 29<sup>th</sup> September, 2024

Venue: Royal Palace, NSCI, Worli, Mumbai

2023

2024

## Scientific Program

28<sup>th</sup> September, 2024 — Day 1

10:40am - 11:10am	<p><b>CHAIRPERSONS:</b> Dr. Sumit Basu, Dr. Shishir Shetty</p> <p><b>Panel Discussion on presented key abstracts of Oropharyngeal Cancers</b></p>
	<p><b>MODERATORS:</b> Dr. Kaustav Talapatra, Dr. Adwaita Gore</p> <p><b>PANELISTS:</b> Dr. Sarbani Laskar, Dr. Kinjal Jani, Dr. Lovin Wilson, Dr. Devendra Chaukar, Dr. Sudhir Nair, Dr. Vinay Babu, Dr. Mandar Deshpande, Dr. Avinash Talele</p>
11:10am - 11:20am	Tea/Coffee Break
<b>Session 3: Key abstracts to be presented on Nasopharyngeal Cancer</b>	
11:20am - 11:30am	<p><b>CHAIRPERSONS:</b> Dr. Vikram Kekatpure, Dr. Nikhilesh Borkar</p> <hr/> <p><b>Reviewer:</b> Dr. Harsh Sahu</p> <p>Endostar combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone for locoregionally advanced nasopharyngeal carcinoma (LA-NPC): A phase III, prospective, randomised-controlled, multicenter clinical trial</p> <p><b>Author:</b> Min Kang</p> <p><b>Citation:</b> ASCO Abstract: 6002</p> <hr/> <p>Sequential chemoradiotherapy versus induction chemotherapy plus concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: A multicentre, open-label, non-inferiority, randomised, phase 3 trial</p> <p><b>Author:</b> Chaosu Hu (Shanghai, China)</p> <p><b>Citation:</b> ASCO 2024 Abstract 6075</p>

Click on the link below for registration  
<https://riverroute.in/arhnc2024>

Managed by  
**riverroute**

Organized by



Supported by



# 7<sup>th</sup> Annual International Review in Head & Neck Cancers

28<sup>th</sup> - 29<sup>th</sup> September, 2024

Venue: Royal Palace, NSCI, Worli, Mumbai

2023

2024

## Scientific Program

28<sup>th</sup> September, 2024 — Day 1

11:30am - 11:40am	<p><b>Reviewer: Dr. Aman Sharma</b></p> <p>Hyperfractionation compared with standard fractionation in intensity-modulated radiotherapy for patients with locally advanced recurrent nasopharyngeal carcinoma: A multicentre, randomised, open-label, phase 3 trial  <b>Author:</b> Rui You  <b>Citation:</b> Lancet 2023 Mar 18;401(10380):917-927</p>
	<p>Efficacy and toxicities of elective upper-neck irradiation versus whole-neck irradiation of the uninvolved neck in patients with nasopharyngeal carcinoma: A meta-analysis  <b>Author:</b> Xiaoxu Ding  <b>Citation:</b> Radiother Oncol. 2023 Nov:188:109860</p>
11:40am - 11:50am	<p><b>Reviewer: Dr. Monali Swain</b></p> <p>The SINTART 1 study. A phase II non-randomised controlled trial of induction chemotherapy, surgery, photon-, proton- and carbon ion-based radiotherapy integration in patients with locally advanced resectable sinonasal tumours  <b>Author:</b> Carlo Resteghini  <b>Citation:</b> Eur J Cancer. 2023 Jul:187:185-194</p>
	<p>The SINTART 2 Study. A phase II non-randomised controlled trial of induction chemotherapy, photon-, proton- and carbon-ion-based radiotherapy integration in patients with locally advanced unresectable sinonasal tumours  <b>Author:</b> Paolo Bossi  <b>Citation:</b> Eur J Cancer. 2023 Jul:187:134-143</p>

Click on the link below for registration  
<https://riverroute.in/arhnc2024>

Managed by



Organized by



Supported by



# 7<sup>th</sup> Annual International Review in Head & Neck Cancers

28<sup>th</sup> - 29<sup>th</sup> September, 2024

Venue: Royal Palace, NSCI, Worli, Mumbai

2023

2024

## Scientific Program

28<sup>th</sup> September, 2024 — Day 1

11:50am - 12:00pm	<p><b>Reviewer: Dr. Rakesh Katna</b></p> <p>Phase II randomized trial of chemotherapy followed by surgery and PORT versus surgery and PORT for organ preservation of T3 and T4a (selected T4b) sinonasal squamous cell carcinoma (SNC): A trial of the ECOG-ACRIN Cancer Research Group (EA3163)  <b>Author:</b> Nabil F. Saba (Atlanta, United States of America, GA)  <b>Citation:</b> ESMO 2024. Abstract 850MO</p>
<p>Endoscopic surgery versus intensity-modulated radiotherapy in locally advanced recurrent nasopharyngeal carcinoma: a multicenter, case-matched comparison.  <b>Author:</b> Yibin Liu  <b>Citation:</b> J of Otolaryngol - Head &amp; Neck Surg 52, 72 (2023)</p>	<p><b>Reviewer: Dr. Laboni Sarkar</b></p> <p>Phase II open-label randomized study of pembrolizumab with or without bevacizumab in platinum-resistant recurrent/metastatic nasopharyngeal carcinoma (R/M NPC)  <b>Author:</b> Wan Qin Chong (Singapore, Singapore)  <b>Citation:</b> ESMO 2024 Abstract 848MO</p>
12:00pm - 12:10pm	<p>Adjuvant PD-1 blockade with camrelizumab in high-risk locoregionally advanced nasopharyngeal carcinoma (DIPPER): A multicenter, open-label, phase 3, randomized controlled trial  <b>Author:</b> Xu Liu, MD  <b>Citation:</b> ASCO Abstract: LBA6000</p>

Click on the link below for registration  
<https://riverroute.in/arhnc2024>

Managed by



Organized by



Supported by



# 7<sup>th</sup> Annual International Review in Head & Neck Cancers

28<sup>th</sup> - 29<sup>th</sup> September, 2024

Venue: Royal Palace, NSCI, Worli, Mumbai

2023

2024

## Scientific Program

28<sup>th</sup> September, 2024 — Day 1

	<p>Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial</p> <p><b>Author:</b> Li-Ting Liu</p> <p><b>Citation:</b> Lancet Oncol., 2023 Jul;24(7):798-810</p>
12:10pm - 12:55pm	<p><b>CHAIRPERSONS:</b> Dr. Hitendra Patil, Dr. Chanchal Goswami</p> <p><b>Panel discussion on presented abstracts in Nasopharyngeal Cancer</b></p> <p><b>MODERATORS:</b> Dr. Kshitij Joshi, Dr. Sanjay M.H.</p> <p><b>PANELISTS:</b> Dr. Nikhil Kalyani, Dr. Bhavin Visariya, Dr. Amit Chakraborty, Dr. Vikas Talreja, Dr. Monali Swain, Dr. Rakesh Katna, Dr. Darshit Shah, Dr. Pritam Jain, Dr. Sandeep De</p>
01:00pm - 01:45pm	Lunch
01:45pm - 06:00pm	<p><b>Session Coordinators:</b> Dr. Ramjas Prajapati, Dr. Harsh Sahu</p> <p><b>Session 4 Key abstracts to be presented on Supportive Care in H&amp;N Cancers</b></p>
01:45pm - 01:55pm	<p><b>CHAIRPERSONS:</b> Dr. Nagraj Huilgol, Dr. Mandar Deshpande</p> <p><b>Reviewer:</b> Dr. Deepanjali Andulkar</p> <p>Streptococcus salivarius K12 Alleviates Oral Mucositis in Patients Undergoing Radiotherapy for Malignant Head and Neck Tumors: A Randomized Controlled Trial.</p> <p><b>Author:</b> Xingchen Peng.</p> <p><b>Citation:</b> J Clin Oncol. 2024 Apr 20;42(12):1426-1435</p>

Click on the link below for registration  
<https://riverroute.in/arhnc2024>

Managed by  
**riverroute**

Organized by



Supported by



# 7<sup>th</sup> Annual International Review in Head & Neck Cancers

28<sup>th</sup> - 29<sup>th</sup> September, 2024

Venue: Royal Palace, NSCI, Worli, Mumbai

2023

2024

## Scientific Program

28<sup>th</sup> September, 2024 — Day 1

	<p>Salivary Electrostimulation in the Treatment of Radiation Therapy-Induced Xerostomia (-2): A Multicenter, Randomized, Double-Masked, Sham-Controlled, Phase 3 Trial</p> <p><b>Author:</b> Int J Radiat</p> <p><b>Citation:</b> Oncol Biol Phys</p>
01:55pm - 02:05pm	<p><b>Reviewer:</b> <b>Dr. Anuj Shah</b></p> <p>The efficacy of Kinesio taping on lymphedema following head and neck cancer therapy: a randomized, double blind, sham-controlled trial</p> <p><b>Author:</b> Sevgi Atar</p> <p><b>Citation:</b> Physiother Theory Pract 2023 Sep2;39(9):1832-1846</p>
	<p>Evaluation of Anterolateral Thigh Fascia Lata Rescue Flap for Mandibular Osteoradionecrosis.</p> <p><b>Author:</b> Khashayar Arianpour</p> <p><b>Citation:</b> JAMA Otolaryngol Head Neck Surg., 2023 Jul 1;149(7):621-627</p>
02:05pm - 02:15pm	<p><b>Reviewer:</b> <b>Dr. Purvi Rathod</b></p> <p>Weekly Adaptive Radiotherapy vs Standard Intensity-Modulated Radiotherapy for Improving Salivary Function in Patients With Head and Neck Cancer: A Phase 3 Randomized Clinical Trial</p> <p><b>Author:</b> Joël Castelli</p> <p><b>Citation:</b> JAMA Oncol. 2023 Aug 1;9(8):1056-1064</p>
	<p>A systematic review and meta-analysis of osteoradionecrosis following proton therapy in patients with head and neck cancer</p> <p><b>Author:</b> Kun-Wei Chiu</p> <p><b>Citation:</b> Oral Oncol 2024 Jan;148:106649</p>

Click on the link below for registration  
<https://riverroute.in/arhnc2024>

Managed by



Organized by



Supported by



# 7<sup>th</sup> Annual International Review in Head & Neck Cancers

28<sup>th</sup> - 29<sup>th</sup> September, 2024

Venue: Royal Palace, NSCI, Worli, Mumbai

2023

2024

## Scientific Program

28<sup>th</sup> September, 2024 — Day 1

02:15pm - 02:25pm	<p><b>Reviewer: Ms. Divyal Vira</b></p> <p>Nutrition and head-neck cancer: A prospective observational study in patients with head neck cancer receiving adjuvant/definitive radiotherapy/chemoradiotherapy  <b>Author:</b> Dr. Chetan Dilip Deshmukh  <b>Citation:</b> ASCO 2024 Abstract e18784</p> <p>Effects of different nutritional support methods on nutritional status and immune function in patients undergoing radiotherapy for head and neck cancer  <b>Author:</b> Jianqi Yang  <b>Citation:</b> Clin Transl Oncol. 2024 Aug 18</p>
02:25pm - 02:35pm	<p><b>Reviewer: Dr. Ajeeta Kulkarni</b></p> <p>Prophylactic Swallowing Therapy During Head-and-Neck Cancer Radiotherapy: Effect of Service-Delivery Mode and Overall Adherence Level on Swallowing Function and Muscle Strength-the PRESTO Trial  <b>Author:</b> Margot Baudelet  <b>Citation:</b> Dysphagia 2024 Apr;39(2):267-281  doi: 10.1007/s00455-023-10609-7</p> <p>Effect of exercise across the head and neck cancer continuum: a systematic review of randomized controlled trials  <b>Author:</b> Alice Avancini  <b>Citation:</b> Support Care Cancer 2023 Nov 4;31(12):670</p>

Click on the link below for registration  
<https://riverroute.in/arhnc2024>

Managed by  
**riverroute**

Organized by



Supported by



# 7<sup>th</sup> Annual International Review in Head & Neck Cancers

28<sup>th</sup> - 29<sup>th</sup> September, 2024

Venue: Royal Palace, NSCI, Worli, Mumbai

2023

2024

## Scientific Program

28<sup>th</sup> September, 2024 — Day 1

02:35pm - 03:05pm

Industry Session 1 - MSD

Role of IO and it's sequencing strategy in the management of HNSCC

Speaker - Dr. Amit Bhatt

Session 5 Key abstracts to be presented on Targeted Therapy / Bio-Marker

CHAIRPERSONS: **Dr. Shailesh Bondarde, Dr. Amrit Kaler**

03:05pm - 03:20pm

Reviewer: **Dr. Bhuvan Chugh**

BRAF-MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas

Author: Priscilla K Brastianos

Citation: N Engl J Med. 2023 Jul 13;389(2):118-126

Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer

Author: Julien Hadoux

Citation: N Engl J Med. 2023 Nov 16;389(20):1851-1861

Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma

Author: Jessica C Hassel

Citation: N Engl J Med. 2023 Dec 14;389(24):2256-2266

A phase II study evaluating tipifarnib in mHRAS, recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) (AIM-HN study)

Author: A. L. Ho

Citation: ESMO 2023 LBA47 Abstract | Volume 34, Supplement 2, S1286-S1287, October 2023

Click on the link below for registration  
<https://riverroute.in/arhnc2024>

Managed by

riverroute®

Organized by



Supported by



# 7<sup>th</sup> Annual International Review in Head & Neck Cancers

**28<sup>th</sup> - 29<sup>th</sup> September, 2024**

**Venue: Royal Palace, NSCI, Worli, Mumbai**

**2023**

**2024**

## Scientific Program

**28<sup>th</sup> September, 2024** — Day 1

<p>03:20pm - 03:35pm</p>	<p><b>Reviewer: Dr. Neha Mittal</b></p> <p>Tumour-agnostic plasma assay for circulating tumour DNA predicts outcome in recurrent and/or metastatic squamous cell carcinoma of the head and neck treated with a PD-1 inhibitor  <b>Author:</b> Natasha Honore  <b>Citation:</b> Eur J Cancer. 2023 Dec;195:113372</p> <p>Personalized Biomarker-Based Umbrella Trial for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: KCSG HN 15-16 TRIUMPH Trial  <b>Author:</b> Bhumsuk Keam  <b>Citation:</b> J Clin Oncol. 2024 Feb 10;42(5):507-517</p> <p>Tumor-agnostic plasma assay for circulating tumor DNA detects minimal residual disease and predicts outcome in locally advanced squamous cell carcinoma of the head and neck  <b>Author:</b> N Honore  <b>Citation:</b> Ann Oncol.,2023 Dec;34(12):1175-1186</p>
<p>03:35pm - 04:15pm</p>	<p><b>CHAIRPERSONS: Dr. Kumar Prabhash, Dr. Rajat Saha</b></p> <p><b>Panel discussion on Precision Oncology and biomarkers in Head and Neck Cancers</b></p> <p><b>MODERATOR: Dr. B. K. Smruti</b></p> <p><b>PANELISTS: Dr. Kiran Tamkhane, Dr. Vanita Norohna, Dr. Omshree Shetty, Dr. Jay Mehta, Dr. Vijay Sharnagat, Dr. Bhuvan Chugh</b></p>

Click on the link below for registration  
<https://riverroute.in/arhnc2024>

Managed by



Organized by



Supported by



# 7<sup>th</sup> Annual International Review in Head & Neck Cancers

28<sup>th</sup> - 29<sup>th</sup> September, 2024

Venue: Royal Palace, NSCI, Worli, Mumbai

2023

2024

## Scientific Program

28<sup>th</sup> September, 2024 — Day 1

04:15pm - 04:25pm	<p><b>Reviewer: Dr. Anuj Kumar</b></p> <p>Oncologic Safety of Close Margins in Patients With Low-to Intermediate-Grade Major Salivary Gland Carcinoma.  <b>Author:</b> Mirabelle Sajisevi  <b>Citation:</b> JAMA Otolaryngol Head Neck Surg., 2024 Feb 1;150(2):107-116</p> <p>Long-Term Outcomes and Risk Factors of Radiofrequency Ablation for T1N0M0 Papillary Thyroid Carcinoma  <b>Author:</b> Xinyang Li  <b>Citation:</b> JAMA Surg 2024 Jan 1;159(1):51-58</p>
04:25pm - 04:35pm	<p><b>Reviewer: Dr. Ekta Vala</b></p> <p>Phase II study of trastuzumab deruxtecan in patients with HER2-positive recurrent/metastatic salivary gland cancer: results from the MYTHOS trial  <b>Author:</b> Ichiro Kinoshita (Sapporo, Japan)  <b>Citation:</b> ESMO 2024. Abstract 8490</p> <p>Radiotherapy and paclitaxel plus pazopanib or placebo in anaplastic thyroid cancer (NRG/RTOG 0912): a randomised, double-blind, placebo-controlled, multicentre, phase 2 trial  <b>Author:</b> Eric J Sherman  <b>Citation:</b> Lancet Oncol 2023 Feb;24(2):175-186</p>
04:35pm - 04:45pm	<p><b>Reviewer: Dr. Devanshee Shah</b></p> <p>Neoadjuvant tyrosine kinase inhibitor therapy in locally advanced differentiated thyroid cancer: a single centre case series  <b>Author:</b> J J Y Yeo  <b>Citation:</b> J Laryngol Otol., 2023 Nov;137(11):1237-1243</p>

Click on the link below for registration  
<https://riverroute.in/arhnc2024>

Managed by  
**riverroute**

Organized by



Supported by



# 7<sup>th</sup> Annual International Review in Head & Neck Cancers

28<sup>th</sup> - 29<sup>th</sup> September, 2024

Venue: Royal Palace, NSCI, Worli, Mumbai

2023

2024

## Scientific Program

28<sup>th</sup> September, 2024 — Day 1

	Carcinomas of the external auditory canal: Management and results: A multicenter REFCOR propensity score matching study <b>Author:</b> Esteban Brenet <b>Citation:</b> Eur J Cancer. 2024 Apr;201:113922
	<b>CHAIRPERSON:</b> Dr. Sudesh Phanse, Dr. Sandeep De, Dr. Suvarna Achrekar
04:45pm - 05:15pm	<b>Panel discussion presented publications of Thyroid / Salivary Gland</b>
	<b>MODERATOR:</b> Dr. Nandini Menon <b>PANELISTS:</b> Dr. Rajat Saha, Dr. Manu Prasad, Dr. Goutam Panda, Dr. Shivam Shingla, Dr. Anuj Kumar, Dr. Kajari Bhattacharya
05:15pm - 05:30pm	<b>Hi-Tea Session</b>
05:30pm - 06:00pm	<b>Industry Session 2 - Alkem</b>
05:30pm - 05:40pm	Addressing Advanced Oral Cancers in India with targeted chemotherapy
05:40pm - 06:00pm	<b>Case Based Panel Discussion: Sequencing Cetuximab with Immunotherapy: Response Rates in Bulky Tumors</b>
06:00pm - 06:15pm	<b>Industry Session 3 - ThermoFisher</b>
06:00pm - 06:15pm	Optimizing Cancer Research workflows with Oncomine <b>Speaker - Mr. Pravin Nilawe</b>
06:15pm - 07:15pm	<b>Students Quiz</b>
	<b>Quiz Master - Dr. Sunil Chopade, Dr. Kunal Jobunputra</b>
08:00pm Onwards	<b>Dinner</b>

Click on the link below for registration  
<https://riverroute.in/arhnc2024>

Managed by

riverroute®

Organized by



Supported by



# 7<sup>th</sup> Annual International Review in Head & Neck Cancers

28<sup>th</sup> - 29<sup>th</sup> September, 2024

Venue: Royal Palace, NSCI, Worli, Mumbai

2023

2024

## Scientific Program

29<sup>th</sup> September, 2024 — Day 2

09:00am - 01:00pm	<p><b>Session Coordinators:</b> Dr. Deep Vora, Dr. Laxma Reddy</p> <p><b>Session 6 Key abstracts to be presented on LA - HNSCC</b></p>
09:00am - 09:15am	<p><b>CHAIRPERSONS:</b> Dr. Sanjay Dudhat, Dr. Vikram Sanghavi</p> <p><b>Reviewer:</b> Dr. Deep Vora</p> <p>MACH-EGFR: Individual patient data (IPD) meta-analysis of anti-EGFR monoclonal antibodies (Ab) in patients (pts) with locally advanced (LA) squamous cell carcinomas of head and neck (SCCHN)ESMO 2023 Abstract 8570  <b>Author:</b> P. Blanchard  <b>Citation:</b> ABSTRACT   VOLUME 34, SUPPLEMENT 2, S556, OCTOBER 2023</p> <p>Long term results of a randomized phase III study of nimotuzumab in combination with concurrent radiotherapy and cisplatin versus radiotherapy and cisplatin alone, in locally advanced squamous cell carcinoma of the head and neck  <b>Author:</b> Vijay Maruti Patil  <b>Citation:</b> ASCO Abstract LBA6092</p>
09:15am - 09:25am	<p><b>Reviewer:</b> Dr. Sunil Chopade</p> <p>Neoadjuvant chemotherapy for locally advanced head and neck squamous cell carcinoma - Is it still relevant? A practice pattern survey among oncologists of India  <b>Author:</b> Anis Bandyopadhyay  <b>Citation:</b> J Cancer Res Ther. 2023 Jul-Sep;19(5):1316-1323</p> <p>Neoadjuvant-adjuvant pembrolizumab in resectable advanced basal cell carcinoma of the head and neck: An open-label, single-arm, phase 1b trial  <b>Author:</b> Grace M. Jones  <b>Citation:</b> AACR Abstract 7518:Proffered paper. Cancer Res (2024) 84(6_Supplement): 7518</p>

Click on the link below for registration  
<https://riverroute.in/arhnc2024>

Managed by



Organized by



Supported by



# 7<sup>th</sup> Annual International Review in Head & Neck Cancers

28<sup>th</sup> - 29<sup>th</sup> September, 2024

Venue: Royal Palace, NSCI, Worli, Mumbai

2023

2024

## Scientific Program

29<sup>th</sup> September, 2024 — Day 2

09:25am - 09:35am

**Reviewer: Dr. Ramjas Prajapati**

Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial

**Author:** Jean-Pascal Machiels

**Citation:** Lancet Oncol., 2024 May;25(5):572-587

A Multicenter Evaluation of Different Chemotherapy Regimens in Older Adults With Head and Neck Squamous Cell Carcinoma Undergoing Definitive Chemoradiation

**Author:** Alexander Rühle

**Citation:** Int J Radiat Oncol Biol Phys 2024 Apr 1;118(5):1282-1293

09:35am - 09:45am

**Reviewer: Dr. Mukul Roy**

Comparing the oncologic outcomes of proton therapy and intensity-modulated radiation therapy for head and neck squamous cell carcinoma.

**Author:** Chia-Lun Chang.

**Citation:** Radiotherapy and Oncology 190:109971.

Acute Toxicity Results from the Randomized Assessment of Cisplatin Dosing Interval for Ototoxicity (RADIO) Trial Comparing Chemoradiation (CRT) with Cisplatin Q3weekly to Weekly for Locally Advanced Squamous Cell Carcinoma of the Head and neck (LASCCHN).

**Author:** Int J Radiat.

**Citation:** Oncol Biol Phys.

Click on the link below for registration  
<https://riverroute.in/arhnc2024>

Managed by

riverroute®

Organized by



Supported by



# 7<sup>th</sup> Annual International Review in Head & Neck Cancers

28<sup>th</sup> - 29<sup>th</sup> September, 2024

Venue: Royal Palace, NSCI, Worli, Mumbai

2023

2024

## Scientific Program

29<sup>th</sup> September, 2024 — Day 2

09:45am - 09:55am	<p><b>Reviewer: Dr. Richa Vaish</b></p> <p>Diagnostic accuracy of intraoperative margin assessment techniques in surgery for head and neck squamous cell carcinoma: A meta-analysis.  <b>Author:</b> James A Higginson.  <b>Citation:</b> Oral Oncol. 2023 Jul;142:106419.</p> <p>Prognostic Value of Radiological Extranodal Extension Detected by Computed Tomography for Predicting Outcomes in Patients With Locally Advanced Head and Neck Squamous Cell Cancer Treated With Radical Concurrent Chemoradiotherapy.  <b>Author:</b> Abhishek Mahajan.  <b>Citation:</b> Front Oncol. 2022 May 27;12:814895.</p>
09:55am - 10:25am	<p><b>Industry Session 4 - ERIS Life Sciences</b></p> <p>LBA6092- Long term results of a randomized phase III study of Nimotuzumab with concurrent chemoradiation versus chemoradiation alone in locally advanced squamous cell carcinoma of head and neck  <b>Speaker - Dr. Nandini Menon</b></p>
10:25am - 11:10am	<p><b>CHAIRPERSONS: Dr. Sudeep Sarkar, Dr. Dilip Nikam</b></p> <p><b>Panel discussion presented publications of LA HNSCC</b></p>
11:10am - 11:20am	<p><b>MODERATOR: Dr. Vijay Patil</b></p> <p><b>PANELISTS: Dr. Mukul Roy, Dr. Rohit Malde, Dr. Yashwant Kashyap, Dr. Shriniwas Kulkarni, Dr. Tarachand Gupta, Dr. Ravikant Singh, Dr. Alok Goel</b></p>
11:10am - 11:20am	Tea/Coffee Break

Click on the link below for registration  
<https://riverroute.in/arhnc2024>

Managed by



Organized by



Supported by



# 7<sup>th</sup> Annual International Review in Head & Neck Cancers

28<sup>th</sup> - 29<sup>th</sup> September, 2024

Venue: Royal Palace, NSCI, Worli, Mumbai

2023

2024

## Scientific Program

29<sup>th</sup> September, 2024 — Day 2

11:20am - 11:35am

Industry Session 5 - Dr. Reddy's Laboratories Ltd.

Randomized, double-blind, phase III study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC)

Speaker - Dr. Akhil Kapoor

Session 7 Key abstracts to be presented on R/M - HNSCC

CHAIRPERSONS: Dr. Devendra Pal, Dr. Ranjeet Bajpai

11:35am - 11:45am

Reviewer: Dr. Akhil Kapoor

Long term results of phase 3 randomized study evaluating the addition of low dose nivolumab to palliative chemotherapy in head and neck cancer.

Author: Vijay Maruti Patil.

Citation: ASCO Abstract LBA6054.

Phase 3 randomized study for evaluation of physician choice Rx versus best supportive care as second-line or beyond therapy in head and neck cancer with poor performance status.

Author: Vijay Maruti Patil.

Citation: ASCO Abstract: LBA6019.

11:45am - 11:55am

Reviewer: Dr. Kshitij Domadia

Subsequent chemotherapy with paclitaxel plus cetuximab-based chemotherapy following immune checkpoint inhibitor in recurrent or metastatic squamous cell carcinoma of the head and neck. Hideki Tanaka., Front. Oncol.

Author: Hideki Tanaka.

Citation: Front. Oncol., 21 November 2023, Sec. Head and Neck Cancer Volume 13 - 2023.

Click on the link below for registration  
<https://riverroute.in/arhnc2024>

Managed by

riverroute®

Organized by



Supported by



# 7<sup>th</sup> Annual International Review in Head & Neck Cancers

28<sup>th</sup> - 29<sup>th</sup> September, 2024

Venue: Royal Palace, NSCI, Worli, Mumbai

2023

2024

## Scientific Program

29<sup>th</sup> September, 2024 — Day 2

	<p>Platinum and taxane (PT) plus immunotherapy versus immunotherapy alone in patients with recurrent/metastatic (R/M) head and neck cancer (HNSCC).</p> <p><b>Author:</b> M. Bonomi.</p> <p><b>Citation:</b> ESMO 2023 930P VOLUME 34, SUPPLEMENT 2, S586, OCTOBER 2023.</p>
11:55am - 12:05pm	<p><b>Reviewer:</b> <b>Dr. Vijai Simha</b></p> <p>Sacituzumab govitecan (SG) in patients (pts) with relapsed/refractory (R/R) advanced head and neck squamous cell carcinoma (HNSCC): Results from the phase II TROPiCS-03 basket trial. ESMO 2023 859MO</p> <p><b>Author:</b> L. Michel.</p> <p><b>Citation:</b> ABSTRACT  VOLUME 34, SUPPLEMENT 2, S558, OCTOBER 2023.</p>
	<p>REWRITE-GORTEC 2018-02: Radiotherapy-durvalumab without prophylactic neck irradiation in squamous cell carcinoma of the head and neck.</p> <p><b>Author:</b> Joël Castelli (Rennes, France).</p> <p><b>Citation:</b> ESMO 2024 852MO.</p>
12:05pm - 12:20pm	<p><b>Reviewer:</b> <b>Dr. Alok Goel</b></p> <p>A phase IV study of EXTREME regimen versus nivolumab plus paclitaxel and cisplatin/carboplatin-based regimen in recurrent or metastatic squamous cell carcinoma of the head and neck.</p> <p><b>Author:</b> A.D. Khadela.</p> <p><b>Citation:</b> ABSTRACT  VOLUME 9, SUPPLEMENT 1, 102361, FEBRUARY 2024.</p>

Click on the link below for registration  
<https://riverroute.in/arhnc2024>

Managed by



Organized by



Supported by



# 7<sup>th</sup> Annual International Review in Head & Neck Cancers

28<sup>th</sup> - 29<sup>th</sup> September, 2024

Venue: Royal Palace, NSCI, Worli, Mumbai

2023

2024

## Scientific Program

29<sup>th</sup> September, 2024 — Day 2

	<p>Intensity-Modulated Reirradiation Therapy With Nivolumab in Recurrent or Second Primary Head and Neck Squamous Cell Carcinoma: A Nonrandomized Controlled Trial.  <b>Author:</b> Nabil F Saba.  <b>Citation:</b> JAMA Oncol. 2024 Jul 1;10(7):896-904.</p> <p>Nivolumab for Patients With High-Risk Oral Leukoplakia: A Non-randomized Controlled Trial  <b>Author:</b> Glenn J Hanna.  <b>Citation:</b> JAMA Oncol. 2024 Jan 1;10(1):32-41.</p>
12:20pm - 01:05pm	<p><b>CHAIRPERSONS:</b> Dr. S. H. Advani, Dr. Reetu Jain</p> <p>Cellular Therapies Update  <b>Speaker - Dr. Vijay Patil</b></p>
01:05pm - 01:45pm	<p><b>Panel discussion presented publications of R/M HNSCC</b></p> <p><b>MODERATOR:</b> Dr. Vanita Noronha</p> <p><b>PANELISTS:</b> Dr. Mubarakunnisa Tonse, Dr. Uma Dangi, Dr. Siddharth Turkar, Dr. Arun Chandrasekharan, Dr. Ashay Karpe, Dr. Gunjesh Singh, Dr. Bhavesh Poladia, Dr. Annu Rajpurohit</p>
01:45pm - 01:50pm	<p><b>Vote of Thanks</b></p>
01:50pm Onwards	<p><b>Lunch and Departure</b></p>

Click on the link below for registration  
<https://riverroute.in/arhnc2024>

Managed by

riverroute®

Introducing

# Roche's First Tumor Agnostic targeted therapy

 **ROZLYTREK™**  
entrectinib 100mg | 200mg capsules

For the  
Rare and  
Relentless



Approved in India for the treatment of:

- ▶ **Adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive.**
- ▶ **Adult and pediatric patients 12 years of age and older with solid tumors that:**
  - ▶ Have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation,
  - ▶ Are metastatic or where surgical resection is likely to result in severe morbidity,
  - ▶ Have progressed following treatment or have no satisfactory alternative therapy.


Please use the QR code/click on the link for the latest Prescribing Information (PI)



[https://bit.ly/Roche\\_Rozlytrek\\_PI](https://bit.ly/Roche_Rozlytrek_PI)


The image features the ThermoFisher Scientific logo centered on a white background. The logo consists of the word "ThermoFisher" in a bold, red, sans-serif font, with the "F" in "Fisher" having a distinctive shape. Below it, the word "SCIENTIFIC" is written in a smaller, black, all-caps, sans-serif font. The background is decorated with flowing, wavy red lines that create a sense of movement and depth, framing the central text.

**ThermoFisher**  
SCIENTIFIC



**CINV** prevention throughout  
● **5 days** post-chemotherapy  
with simplified regimen<sup>2</sup>

Single-dose, **Easy to Swallow tablets of Nykron** offers more convenience  
in both acute & delayed phase of CINV<sup>1,2</sup>



● 1-day **Nykron** is proven to be  
**more effective** than 3-day APR<sup>4,5</sup>

Lesser incidence of breakthrough  
**CINV** with **NEPA** than APR<sup>5</sup>



● **NEPA** is comparatively **more economical** than Fosaprepitant<sup>3</sup>

**CINV:** Chemotherapy-induced nausea & vomiting; **NEPA:** Netupitant + Palonosetron; **APR:** Aprepitant; **NCCN:** National Comprehensive Cancer Network; **MASCC:** Multinational Association of Supportive Care in Cancer; **ESMO:** European Society for Medical Oncology.

**References:**

1. Lorusso V, et al. Management of chemotherapy-induced Nausea & Vomiting (CINV): a short review on the role of Netupitant-Palonosetron (NEPA). Core evidence. 2020;15:21
2. Lorusso V. Management of chemotherapy-induced nausea & vomiting by risk profile: role of netupitant/palonosetron. Ther Clin Risk Manag. 2016;12:917-925. Published 2016 Jun 7. doi :10.2147/TCRM.S89215
3. Data on file
4. J Clin Oncol 39, 2021 (suppl 15; abstr 12091)
5. Navari RM, et al. Single-dose netupitant/palonosetron versus 3-day aprepitant for preventing chemotherapy-induced nausea & vomiting: a pooled analysis. Future Oncol. 2021; 17(23):3027-3035.

# TRANSFORMING

Head and Neck cancer  
patient journey with

<sup>Rx</sup>  
**Lupitux**  
Cetuximab 100 mg/ 20 ml Injection

